Finance

Lists
CLDX:NASDAQ
Celldex Therapeutics Inc
$41.06
+5.15%
(+2.01) 1D
$41.06
0.00% (0.00)
After hours
Closed: Aug 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLDX...
Open
$39.36
High
$41.15
Low
$38.86
Mkt. cap
3.22B
Avg. vol.
1.18M
Volume
788.88K
52-wk high
$41.15
52-wk low
$19.72
EPS
-$4.27
Beta
0.87
Shares outstanding
78.49M
No. of employees
198
Open
$39.36
High
$41.15
Low
$38.86
Mkt. cap
3.22B
Avg. vol.
1.18M
Volume
788.88K
52-wk high
$41.15
52-wk low
$19.72
EPS
-$4.27
Beta
0.87
Shares outstanding
78.49M
No. of employees
198
News stories
From sources across the web
About Celldex Therapeutics Inc
CEO-
Employees198
Founded1983
HeadquartersHampton, New Jersey, United States
SectorBiotechnology
Websitecelldex.com
Analyst ratings
Based on 14 analysts giving stock ratings to CLDX in the past 3 months
Strong buy
Buy
13
Hold
1
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for CLDX in the last 3 months.
Highest
Current $41.06
$100.00 (+143.55%)
Average
$56.92 (+38.63%)
Lowest
$34.00 (-17.19%)
Analyst
Recommendation
Action
Price target
Projected
Date
Derek Archila
Wells Fargo
Buy
Reiterated
$72.00
+75.4%
07/29/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$56.00
+36.4%
07/25/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$42.00
+2.3%
07/22/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$68.00
+65.6%
07/22/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$61.00
+48.6%
07/21/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$40.00
-2.6%
07/22/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$60.00
+46.1%
07/22/2026
Richard Law CFA
Goldman Sachs
Hold
Reiterated
$34.00
-17.2%
07/22/2026
Thomas Smith
Leerink Partners
Buy
Maintained
$70.00
+70.5%
07/22/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$100.00
+143.5%
07/20/2026
David Dai
UBS
Buy
Maintained
$45.00
+9.6%
06/16/2026
Andy Chen
Wolfe Research
Buy
Maintained
$44.00
+7.2%
06/14/2026
Etzer Darout
Barclays
Buy
Reiterated
$48.00
+16.9%
05/08/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
730.00K
-
121.00K
15.00K
Cost of goods sold
54.20M
62.93M
75.33M
73.00M
Cost of revenue
54.20M
62.93M
75.33M
73.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.39M
10.69M
11.94M
11.45M
Operating expense
10.39M
10.69M
11.94M
11.45M
Total operating expenses
64.59M
73.62M
87.27M
84.45M
Operating income
-63.86M
-73.62M
-87.15M
-84.44M
Other non operating income
-
-
-
-
EBT including unusual items
-56.60M
-67.04M
-81.32M
-78.68M
EBT excluding unusual items
-56.60M
-67.04M
-81.32M
-78.68M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-56.60M
-67.04M
-81.32M
-78.68M
Net profit margin
-7,753.42%
-
-67,204.13%
-524,566.67%
Earnings per share
-0.85
-1.01
-1.22
-1.18
Interest and investment income
7.26M
6.57M
5.84M
5.75M
Interest expense
-
-
-
-
Net interest expenses
7.26M
6.57M
5.84M
5.75M
Depreciation and amortization charges
-
-
-
-
EBITDA
-62.98M
-72.79M
-86.34M
-83.58M
Gain or loss from assets sale
2.00K
6.00K
-
3.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps